CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 258 filers reported holding CRISPR THERAPEUTICS AG in Q1 2020. The put-call ratio across all filers is 0.73 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $60,369 | +70.7% | 1,330 | +111.1% | 0.00% | +100.0% |
| Q2 2023 | $35,368 | +24.1% | 630 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $28,495 | +109496.2% | 630 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $26 | -99.9% | 630 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $41,000 | +7.9% | 630 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $38,000 | -5.0% | 630 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $40,000 | -16.7% | 630 | -0.2% | 0.00% | 0.0% |
| Q4 2021 | $48,000 | -39.2% | 631 | -10.6% | 0.00% | -50.0% |
| Q3 2021 | $79,000 | -57.8% | 706 | -38.9% | 0.00% | -60.0% |
| Q2 2021 | $187,000 | +32.6% | 1,156 | 0.0% | 0.01% | +25.0% |
| Q1 2021 | $141,000 | -33.2% | 1,156 | -15.9% | 0.00% | -42.9% |
| Q4 2020 | $211,000 | +627.6% | 1,375 | +292.9% | 0.01% | +600.0% |
| Q3 2020 | $29,000 | +11.5% | 350 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $26,000 | +73.3% | 350 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $15,000 | -28.6% | 350 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $21,000 | – | 350 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 508,558 | $82,330,000 | 27.28% |
| Valiant Capital Management, L.P. | 307,700 | $49,814,000 | 3.74% |
| NEA Management Company, LLC | 1,590,002 | $257,405,000 | 3.35% |
| NIA IMPACT ADVISORS, LLC | 39,891 | $6,458,000 | 3.15% |
| Ikarian Capital, LLC | 200,000 | $32,379,000 | 2.62% |
| Soleus Capital Management, L.P. | 103,114 | $16,693,000 | 2.57% |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 157,334 | $25,471,000 | 2.47% |
| Capital Impact Advisors, LLC | 45,440 | $7,356,000 | 2.37% |
| ARK Investment Management | 7,776,119 | $1,258,876,000 | 2.34% |
| Sassicaia Capital Advisers LLC | 13,513 | $2,188,000 | 2.28% |